In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Dompe Farmaceutici SPA

http://www.dompe.com

Latest From Dompe Farmaceutici SPA

Coronavirus Notebook: Drugs Old & New, Equitable Access To Vaccines, And Vial Supplies

In this edition of the Coronavirus Notebook, an EU consortium uses a supercomputing platform to identify the generic drug raloxifene as a potential COVID-19 treatment, and the World Health Organization proposes a set of principles for distributing a coronavirus vaccine at global level.

Europe International

Italy’s Dompé Taking Legal Action Over COVID-19 Fake News

Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.

Dietary Supplements Italy

Kiadis Raises €28m As Cell Therapy Nears Commercialization

The funding comes as the Dutch biotech closes in on a potential conditional approval and closure of its acquisition of CytoSen.

Financing ImmunoOncology

Australian Orphan Fee Waivers To Expire As Transition Period Ends

The transition period for Australia’s new orphan drug program is coming to an end, and sponsors may need to take action if they want to keep their orphan status - and fee waivers - beyond the end of June. 

Rare Diseases Australia
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register